Insmed Incorporated
INSM
Clasificación en acciones
#1108
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Precio por acción
$95.88
Capitalización bursátil
$20.94B
Cambio (1 día)
0.61%
Cambio (1 año)
-42.90%
País
US
Comercio Insmed Incorporated (INSM)
Categoría
Healthcare
Número de acciones en circulación de Insmed Incorporated (INSM)
Número de acciones en circulación al June 2026: 217.35M
Según los últimos informes financieros y el precio de las acciones de Insmed Incorporated, el número actual de acciones en circulación es 217.35M. Al final de December 2023, la empresa tenía 140.43M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Insmed Incorporated (INSM) desde 2000 hasta 2026
Acciones en circulación al final de cada año
| Año | Acciones en circulación | Cambiar |
|---|---|---|
| 2026 (TTM) | 217.35M | 32.50% |
| 2024 | 164.04M | 16.81% |
| 2023 | 140.43M | 14.14% |
| 2022 | 123.04M | 9.74% |
| 2021 | 112.11M | 14.86% |
| 2020 | 97.61M | 15.43% |
| 2019 | 84.56M | 10.04% |
| 2018 | 76.84M | 15.42% |
| 2017 | 66.58M | 7.64% |
| 2016 | 61.85M | 5.72% |
| 2015 | 58.51M | 35.99% |
| 2014 | 43.02M | 22.99% |
| 2013 | 34.98M | 31.89% |
| 2012 | 26.52M | 13.59% |
| 2011 | 23.35M | 76.21% |
| 2010 | 13.25M | 4.24% |
| 2009 | 12.71M | 4.08% |
| 2008 | 12.21M | 6.49% |
| 2007 | 11.47M | 20.31% |
| 2006 | 9.53M | 95.56% |
| 2005 | 4.87M | 24.47% |
| 2004 | 3.92M | 10.00% |
| 2003 | 3.56M | 7.66% |
| 2002 | 3.31M | 0.59% |
| 2001 | 3.29M | 79.44% |
| 2000 | 1.83M | 0.00% |
Acciones en circulación de empresas similares o competidores
| Empresa | Acciones en circulación | Diferencia | País |
|---|---|---|---|
| 253.90M | 16.82% |
US
|
|
| 396.00M | 82.19% |
US
|
|
| 478.91M | 120.34% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -71.39% |
NL
|
